Interclean Shanghai

Paragonix expands to West Coast in adoption of advanced heart transplant technologies

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Paragonix Technologies announced that its Paragonix SherpaPak Cardiac Transport System (CTS) for donor heart preservation and transport is now being used by Stanford Health Care, the first heart transplant center on the West Coast of the United States to implement the system as standard of care for its heart transplant program.

The first donor heart preserved by Stanford Medicine practitioners using the Paragonix System set a record for the longest recovery — transported across the country by jet and safeguarded for 283 minutes.

Enabling long-distance heart recoveries is an important capability to ensure patients on transplant waitlists can get the heart they desperately need. The Paragonix SherpaPak CTS was designed to provide a controlled environment for donor hearts en-route to patients, a radical advancement from conventional methods.

“We are honored to be part of the life-saving work being accomplished at Stanford,” said Bill Edelman, CEO of Paragonix Technologies. “There are more people in need of heart transplants than there are hearts available. This drives our team’s unyielding commitment to provide a reliable, safe preservation environment for organs undergoing the transplant journey.”

 

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »